Dr Lilly Xu joins ChemPart­ner as vice pres­i­dent

BioSpectrum (Asia) - - People News -

ChemPart­ner an­nounced the ap­point­ment of Lilly Xu, Ph.D. as vice pres­i­dent and the head of Drug Me­tab­o­lism Pharmoki­netic (DMPK) and Ex­ploratory Tox­i­col­ogy at the com­pany head­quar­ters in Shang­hai, China.

Dr Xu has more than 20 years of ex­pe­ri­ence in the area of drug me­tab­o­lism, phar­ma­coki­net­ics and tox­i­col­ogy. She was one of the pioneers in de­vel­op­ing cul­tured hu­man hep­a­to­cytes as a tool to study me­tab­o­lism of xeno­bi­otics and in­duc­tion of P450 isozymes. Prior to join­ing ChemPart­ner, Dr Xu was the Head of the Cen­ter of Pre­dic­tive ADMET at Sanofi/Ica­gen. She re­ceived her Ph.D. in Cell and Molec­u­lar Bi­ol­ogy from Saint Louis Univer­sity.

Since the DMPK and Ex­ploratory Tox­i­col­ogy depart­ment’s in­cep­tion in 2006, it has been one of the most rapidly grow­ing busi­ness units in the com­pany. This growth is a tes­ta­ment to the high-qual­ity per­for­mance and ex­pe­ri­enced lead­er­ship by the sci­en­tific team.

ChemPart­ner’s DMPK and Ex­ploratory Tox­i­col­ogy depart­ment con­sists of bio­an­a­lyt­i­cal (small and large mol­e­cules, dis­cov­ery, and reg­u­lated), in vitro ADME, in vivo phar­ma­coki­net­ics, and tox­i­col­ogy (non-GLP and part­nered GLP) groups. Working closely with Chem­istry, Bi­ol­ogy/Phar­ma­col­ogy, and Bi­o­log­ics, the depart­ment sup­ports trans­la­tional medicine with ex­pe­ri­ence in for­mu­la­tion devel­op­ment, in vitro and in vivo PK ex­trap­o­la­tion, PK/PD cor­re­la­tion, and biomarker anal­y­sis in­clud­ing metabolomics.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.